Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

03 October 2011 Young People With Rare Medical Conditions
Faced With Care Issues and Possible
Healthcare Cuts Make Their Voices Heard

Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, eager to tell elected officials their personal stories. The stories are as varied as the towns and cities from where they hail, places like San Antonio, Pittsburgh, Des Moines and New York.

> Read More
14 September 2011 Plasma Protein Therapies Month Raises Awareness of Rare Diseases And The Importance of Donating Plasma

Every year thousands of people in the United States who suffer with rare and serious disorders such as hemophilia, hereditary angioedema, von Willebrand disease, primary immune deficiencies and inherited respiratory disease receive lifesaving therapies derived from human plasma. These conditions affect people of all ages from children to the elderly, and from all ethnic, racial and socioeconomic backgrounds.

> Read More
06 September 2011 CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research into Neuroimmunology

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership Awards. Established in 2010, this annual global awards program provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.

> Read More
25 August 2011 CSL Behring Receives European Health Authorities’ Approval for Self-Administration of Berinert®

CSL Behring today announced that European health authorities have approved self-administration of Berinert®, a C1-esterase inhibitor (C1-INH) concentrate indicated in Europe for the treatment of acute attacks of hereditary angioedema (HAE), a rare, serious, and sometimes life-threatening genetic disorder.

> Read More
18 July 2011 CSL Behring Donates von Willebrand Factor / Factor VIII Donation to World Federation of Hemophilia

CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication to patients through the World Federation of Hemophilia (WFH). The donation supports WFH’s progress in improving the diagnosis and treatment of bleeding disorders in developing countries through its Global Alliance for Progress (GAP) program. It is part of the commitment CSL Behring has made to WFH to donate two million IUs of FVIII each year for three years. Today’s donation is commercially valued at $1.3 million.

> Read More
Page 26 of 51 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+